HIV infection in children research hub

Comparing a two-drug fixed dose combination containing dolutegravir and lamivudine to the usual three-drug combination for maintenance treatment in children aged 2-14 years with HIV infection living in Europe, Thailand and Africa

This trial looks at whether a simpler two-in-one daily tablet works just as well as standard three-drug treatments for children aged 2 to 14 living with HIV. Researchers want to see if taking fewer medicines keeps HIV controlled while causing fewer side effects as children grow.